Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 2/20 | 0.81 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.81 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.81 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.81 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.81 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.50 |
| ▸ | PPARG | P37231 | 7/20 | 0.50 |
| ▸ | PPARD | Q03181 | 7/20 | 0.50 |
| ▸ | PPARA | Q07869 | 7/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | FABP4 | P15090 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butyric Acid SCHEMBL15610536 | 0.90 | — | — | |
| Butyric Acid SCHEMBL1690482 | 0.90 | — | — | |
| Butyric Acid SCHEMBL27614175 | 0.90 | — | — | |
| Butyric Acid SCHEMBL5571639 | 0.90 | FFAR3 (0.87) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL49424 | 0.90 | — | — | |
| Butyric Acid SCHEMBL991717 | 0.90 | FFAR3 (1.00) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL1332215 | 0.90 | — | — | |
| Butyric Acid SCHEMBL8458708 | 0.90 | FFAR3 (1.00) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL8457839 | 0.90 | FFAR3 (1.00) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL20678495 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115745946-B | Low-temperature preparation method of glycolide and lactide | 中国科学院长春应用化学研究所 | 2024-03-26 | — | — | CN | claimed |
| CN-115650948-B | Preparation method of glycolide-lactide | 中国科学院长春应用化学研究所 | 2023-12-19 | — | — | CN | claimed |
| CN-115745946-A | Low-temperature preparation method of glycolide-lactide | 中国科学院长春应用化学研究所 | 2023-03-07 | — | — | CN | claimed |
| CN-115650948-A | Preparation method of glycolide-lactide | 中国科学院长春应用化学研究所 | 2023-01-31 | — | — | CN | claimed |
| US-12024512-B2 | Cocrystal | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-07-02 | — | — | US | disclosed |
| CN-115745946-B | Low-temperature preparation method of glycolide and lactide | 中国科学院长春应用化学研究所 | 2024-03-26 | — | — | CN | disclosed |
| WO-2023249105-A1 | THERAPEUTIC AGENT OR PREVENTIVE AGENT FOR DRUG-INDUCED MYOCARDIAL DISORDERS | 東レ株式会社 | 2023-12-28 | — | — | WO | disclosed |
| WO-2023249107-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR PERIPHERAL NERVE DISORDER | 東レ株式会社 | 2023-12-28 | — | — | WO | disclosed |
| WO-2023249106-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | 東レ株式会社 | 2023-12-28 | — | — | WO | disclosed |
| CN-115650948-B | Preparation method of glycolide-lactide | 中国科学院长春应用化学研究所 | 2023-12-19 | — | — | CN | disclosed |
| CN-115745946-A | Low-temperature preparation method of glycolide-lactide | 中国科学院长春应用化学研究所 | 2023-03-07 | — | — | CN | disclosed |
| CN-115650948-A | Preparation method of glycolide-lactide | 中国科学院长春应用化学研究所 | 2023-01-31 | — | — | CN | disclosed |
| EP-1484320-A1 | JNK INHIBITOR | Takeda Chemical Industries, Ltd. (JP) | 2004-12-08 | — | — | EP | disclosed |
| EP-1471064-A1 | COUMARIN DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-10-27 | — | — | EP | disclosed |
| US-20040038986-A1 | Carbamate derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-26 | — | — | US | disclosed |
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1340753-A1 | CARBAMATE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
| US-20030139616-A1 | Method of searching for arteriosclerosis inhibitors and shrinkers | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-07-24 | — | — | US | disclosed |
| EP-1302462-A1 | SULFONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-04-16 | — | — | EP | disclosed |
| EP-1277760-A1 | METHOD OF SEARCHING FOR ARTERIOSCLEROSIS INHIBITORS AND SHRINKERS | Takeda Chemical Industries, Ltd. (JP) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038986-A1 | Carbamate derivatives, process for producing the same and use thereof | CFH, F11, F2 | FFAR3 1402/4885HDAC3 29/4885HDAC1 77/4885 |
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | SULT1E1, RRS1, SHH | FFAR3 1514/4885HDAC3 1828/4885HDAC1 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.